Liqun Wu

426 total citations
13 papers, 117 citations indexed

About

Liqun Wu is a scholar working on Hepatology, Surgery and Epidemiology. According to data from OpenAlex, Liqun Wu has authored 13 papers receiving a total of 117 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hepatology, 4 papers in Surgery and 4 papers in Epidemiology. Recurrent topics in Liqun Wu's work include Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). Liqun Wu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Liver Disease Diagnosis and Treatment (4 papers). Liqun Wu collaborates with scholars based in China. Liqun Wu's co-authors include Zusen Wang, Sheng Dong, Zhiqiang Qu, Dingding Wang, Xin Wang, H. Lu, Weidong Guo, Bin Zhang, Jingyu Cao and Hao Zou and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Medicine.

In The Last Decade

Liqun Wu

13 papers receiving 116 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liqun Wu China 6 77 55 31 29 25 13 117
Yoshiro Asahina Japan 9 56 0.7× 43 0.8× 37 1.2× 33 1.1× 22 0.9× 18 152
Ann‐Shing Lee China 5 89 1.2× 49 0.9× 24 0.8× 38 1.3× 18 0.7× 7 118
Jiong-Jie Yu China 6 102 1.3× 54 1.0× 39 1.3× 57 2.0× 37 1.5× 13 160
Danny Orabi United States 7 36 0.5× 29 0.5× 25 0.8× 31 1.1× 12 0.5× 10 91
Riccardo Memeo Italy 4 39 0.5× 35 0.6× 32 1.0× 10 0.3× 22 0.9× 9 101
Leszek Zając Poland 6 27 0.4× 45 0.8× 64 2.1× 10 0.3× 15 0.6× 14 91
Răzvan Grigorie Romania 7 115 1.5× 83 1.5× 54 1.7× 60 2.1× 34 1.4× 18 170
Kazuki Ohya Japan 8 111 1.4× 32 0.6× 33 1.1× 91 3.1× 16 0.6× 24 167
Shufa Yang China 4 56 0.7× 19 0.3× 7 0.2× 30 1.0× 14 0.6× 6 77

Countries citing papers authored by Liqun Wu

Since Specialization
Citations

This map shows the geographic impact of Liqun Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liqun Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liqun Wu more than expected).

Fields of papers citing papers by Liqun Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liqun Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liqun Wu. The network helps show where Liqun Wu may publish in the future.

Co-authorship network of co-authors of Liqun Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Liqun Wu. A scholar is included among the top collaborators of Liqun Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liqun Wu. Liqun Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Zhu, Qingwei, Wei Rao, Junyu Huo, et al.. (2023). Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center. BMC Gastroenterology. 23(1). 28–28. 2 indexed citations
2.
Qiu, Xuan, et al.. (2020). <p>Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib</p>. Cancer Management and Research. Volume 12. 7983–7992. 3 indexed citations
3.
Wang, Zusen, et al.. (2019). Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections. European Journal of Surgical Oncology. 45(9). 1684–1690. 15 indexed citations
4.
Wang, Dingding, Liqun Wu, & Zusen Wang. (2016). Prognosis of hepatocellular carcinoma with bile duct tumor thrombus after R0 resection: a matched study. Hepatobiliary & pancreatic diseases international. 15(6). 626–632. 17 indexed citations
5.
6.
Dong, Sheng, Zusen Wang, Liqun Wu, & Zhiqiang Qu. (2016). Effect of surgical margin in R0 hepatectomy on recurrence-free survival of patients with solitary hepatocellular carcinomas without macroscopic vascular invasion. Medicine. 95(44). e5251–e5251. 23 indexed citations
7.
8.
Guo, Weidong, et al.. (2015). Relationship of different surgical margins with recurrence-free survival in patients with hepatocellular carcinoma.. PubMed. 8(3). 3404–9. 15 indexed citations
9.
Wu, Liqun, et al.. (2014). Prognosis of advanced hepatocellular carcinoma (HCC) in patients undergoing surgery combined with peri- or postoperative treatment with sorafenib.. Journal of Clinical Oncology. 32(3_suppl). 377–377. 1 indexed citations
10.
Pan, Xinting, Liqun Wu, Jingyu Cao, et al.. (2012). Recombinant adenovirus vector-mediated human MDA-7 gene transfection suppresses hepatocellular carcinoma growth in a mouse xenograft model. Journal of Biomedical Research. 26(1). 53–58. 2 indexed citations
11.
Wu, Liqun, et al.. (2008). Can E-cadherin and CD34 be used as indicators of prognosis for hepatocellular carcinoma patients?. Clinical Chemistry and Laboratory Medicine (CCLM). 46(8). 1122–6. 5 indexed citations
12.
Wu, Liqun, et al.. (2004). Efficacy of intra-tumor injection of Kang-Lai-Te in treating transplanted hepatoma in rats.. PubMed. 3(4). 580–4. 12 indexed citations
13.
Wu, Liqun. (2003). Effects of Shenbining on Apoptosis and Experssion of Bax and Bcl-2 in the Kidney of Mesangial Proliferative Glomerulonephritis. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshiro Asahina Breakdown of academic impact, for papers by Ann‐Shing Lee Breakdown of academic impact, for papers by Jiong-Jie Yu Breakdown of academic impact, for papers by Danny Orabi Breakdown of academic impact, for papers by Riccardo Memeo Breakdown of academic impact, for papers by Leszek Zając Breakdown of academic impact, for papers by Răzvan Grigorie Breakdown of academic impact, for papers by Kazuki Ohya Breakdown of academic impact, for papers by Shufa Yang
Rankless by CCL
2026